-
Je něco špatně v tomto záznamu ?
Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls
M. Kolarova, U. Sengupta, A. Bartos, J. Ricny, R. Kayed,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
PubMed
28453485
DOI
10.3233/jad-170048
Knihovny.cz E-zdroje
- MeSH
- Alzheimerova nemoc krev komplikace MeSH
- amyloidní beta-protein krev MeSH
- ELISA MeSH
- kognitivní dysfunkce krev etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty krev MeSH
- proteiny tau krev chemie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stárnutí krev MeSH
- záznam o duševním stavu MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010620
- 003
- CZ-PrNML
- 005
- 20180404142142.0
- 007
- ta
- 008
- 180404s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3233/JAD-170048 $2 doi
- 035 __
- $a (PubMed)28453485
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Kolarova, Michala $u National Institute of Mental Health, Klecany, Czech Republic. Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Tau Oligomers in Sera of Patients with Alzheimer's Disease and Aged Controls / $c M. Kolarova, U. Sengupta, A. Bartos, J. Ricny, R. Kayed,
- 520 9_
- $a Although tau protein was long regarded as an intracellular protein with several functions inside the cell, new evidence has shown tau secretion into the extracellular space. The active secretion of tau could be a physiological response of neurons to increased intracellular amounts of tau during the progression of tau pathology. We looked for potential differences in the serum levels of toxic tau oligomers in regards to cognitive impairment of subjects. We detected tau oligomers in the serum of Alzheimer's disease (AD) patients, but they were also present to some extent in the serum of healthy older subjects where the levels positively correlated with aging (Spearman r = 0.26, p = 0.016). On the contrary, we found lower levels of tau oligomers in the serum of mild cognitive impairment (MCI) (p = 0.033) and MCI-AD (p = 0.006) patients. These results could suggest that clearance of extracellular tau proteins takes place, in part, in the periphery. In the case of MCI patients, the lower levels of tau oligomers could be the result of impaired clearance of tau protein from interstitium to blood and consequent accumulation of tau aggregates in the brain.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a stárnutí $x krev $7 D000375
- 650 _2
- $a Alzheimerova nemoc $x krev $x mok mozkomíšní $x komplikace $7 D000544
- 650 _2
- $a amyloidní beta-protein $x krev $x mok mozkomíšní $7 D016229
- 650 _2
- $a kognitivní dysfunkce $x krev $x etiologie $7 D060825
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a záznam o duševním stavu $7 D008609
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a peptidové fragmenty $x krev $7 D010446
- 650 _2
- $a proteiny tau $x krev $x mok mozkomíšní $x chemie $7 D016875
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sengupta, Urmi $u Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA. Department of Neurology, and Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA.
- 700 1_
- $a Bartos, Ales $u National Institute of Mental Health, Klecany, Czech Republic.
- 700 1_
- $a Ricny, Jan $u National Institute of Mental Health, Klecany, Czech Republic.
- 700 1_
- $a Kayed, Rakez $u Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, TX, USA. Department of Neurology, and Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, USA.
- 773 0_
- $w MED00006350 $t Journal of Alzheimer's disease JAD $x 1875-8908 $g Roč. 58, č. 2 (2017), s. 471-478
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28453485 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180404142221 $b ABA008
- 999 __
- $a ok $b bmc $g 1288105 $s 1007432
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 58 $c 2 $d 471-478 $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
- LZP __
- $a Pubmed-20180404